Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezharmia Tablet Post-marketing Surveillance
jRCT2031220503Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valemetostat in adult T-cell leukemia-lymphoma (ATLL), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Cumulative incidence of adverse events. Started Dec 2022; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2031220503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220503.